Which of the following genetic mutations involved in breast carcinoma
**Core Concept**
Breast carcinoma is a heterogeneous disease involving various genetic mutations that contribute to its development and progression. The most common genetic mutations in breast cancer include those in the TP53, BRCA1, and BRCA2 genes, which are tumor suppressor genes.
**Why the Correct Answer is Right**
The TP53 gene is a critical tumor suppressor gene that encodes for the p53 protein, which regulates cell cycle arrest, DNA repair, and apoptosis in response to DNA damage. Mutations in TP53 lead to the loss of its tumor suppressor function, resulting in uncontrolled cell growth and cancer. TP53 mutations are found in approximately 20-30% of breast cancers and are associated with a poor prognosis.
**Why Each Wrong Option is Incorrect**
* **Option A:** While BRCA1 and BRCA2 mutations are associated with breast cancer, they are primarily linked to ovarian cancer as well. BRCA1 and BRCA2 are involved in DNA repair mechanisms, and their mutations increase the risk of breast and ovarian cancer in women.
* **Option B:** PTEN mutations are associated with Cowden syndrome, a rare genetic disorder that increases the risk of breast, thyroid, and endometrial cancers. However, PTEN mutations are not as common in breast cancer as TP53 mutations.
* **Option C:** HER2 amplification is a common genetic alteration in breast cancer, particularly in estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) tumors. However, it is not a genetic mutation but rather an amplification of the HER2 gene.
**Clinical Pearl / High-Yield Fact**
The TP53 mutation is a "guardian of the genome" that, when mutated, can lead to uncontrolled cell growth and cancer. It is essential to identify TP53 mutations in breast cancer patients to predict their prognosis and guide treatment decisions.
**Correct Answer: C. PTEN mutations are associated with Cowden syndrome, a rare genetic disorder that increases the risk of breast, thyroid, and endometrial cancers. However, PTEN mutations are not as common in breast cancer as TP53 mutations.